Last reviewed · How we verify
opana then placebo then darvocet
opana then placebo then darvocet is a Opioid analgesic (mu-opioid receptor agonist) Small molecule drug developed by University of Rochester. It is currently FDA-approved for Chronic pain (study comparison). Also known as: opana: oxymorphone HCL, darvocet: propoxyphene/acetaminophen, placebo: inactive drug.
This is a study comparing the pain-relief efficacy and safety of oxymorphone (Opana) versus placebo and propoxyphene/acetaminophen (Darvocet) in patients with chronic pain.
This is a study comparing the pain-relief efficacy and safety of oxymorphone (Opana) versus placebo and propoxyphene/acetaminophen (Darvocet) in patients with chronic pain. Used for Chronic pain (study comparison).
At a glance
| Generic name | opana then placebo then darvocet |
|---|---|
| Also known as | opana: oxymorphone HCL, darvocet: propoxyphene/acetaminophen, placebo: inactive drug |
| Sponsor | University of Rochester |
| Drug class | Opioid analgesic (mu-opioid receptor agonist) |
| Target | Mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Opana (oxymorphone) is a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to reduce pain perception. Darvocet (propoxyphene/acetaminophen) combines a weak opioid agonist with a non-opioid analgesic. This appears to be a comparative clinical trial rather than a single drug entity.
Approved indications
- Chronic pain (study comparison)
Common side effects
- Nausea
- Constipation
- Dizziness
- Drowsiness
- Respiratory depression
Key clinical trials
- Lumbar Stenosis Outcomes Research II (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- opana then placebo then darvocet CI brief — competitive landscape report
- opana then placebo then darvocet updates RSS · CI watch RSS
- University of Rochester portfolio CI
Frequently asked questions about opana then placebo then darvocet
What is opana then placebo then darvocet?
How does opana then placebo then darvocet work?
What is opana then placebo then darvocet used for?
Who makes opana then placebo then darvocet?
Is opana then placebo then darvocet also known as anything else?
What drug class is opana then placebo then darvocet in?
What development phase is opana then placebo then darvocet in?
What are the side effects of opana then placebo then darvocet?
What does opana then placebo then darvocet target?
Related
- Drug class: All Opioid analgesic (mu-opioid receptor agonist) drugs
- Target: All drugs targeting Mu-opioid receptor
- Manufacturer: University of Rochester — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Chronic pain (study comparison)
- Also known as: opana: oxymorphone HCL, darvocet: propoxyphene/acetaminophen, placebo: inactive drug
- Compare: opana then placebo then darvocet vs similar drugs
- Pricing: opana then placebo then darvocet cost, discount & access